![Mark Vickery Mark Vickery](https://staticx.zacks.com/images/mugshots/mark_vickery/mark_vickery-8.png)
Top Stock Reports for CVS Health, Marriott & Enbridge
![](https://staticx.zacks.com/images/zt/ztNow_icon2.png)
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Wednesday, August 9, 2017
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including CVS Health (CVS), Marriott (MAR) and Enbridge (ENB). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
CVS Health shares have outperformed the Zacks categorized Drug Stores industry year to date losing -0.4% vs. -4.4%. CVS Health posted better-than-expected second-quarter 2017 with both adjusted EPS and revenues beating expectations. Year-over-year top line growth was driven by a strong Pharmacy Services segment, benefiting from the upside in the Specialty Pharmacy.
The company’s strong PBM selling season is a major positive. However, poor year-over-year Retail/LTC numbers along with margin debacle resulted in a dull earnings performance by the company in the quarter. Despite an unimpressive bottom-line scenario the company has raised the lower-end of its earnings outlook for 2017 raising investors optimism. The Zacks analyst thinks the Omnicare and Target Pharmacy buyouts should drive enterprise value significantly in the days ahead.
(You can read the full research report on CVS Health here >>>).
Shares of Marriott have outperformed the Zacks Hotels industry in the year-to-date period (the stock is up +25.7% vs. +3.3% gain for the industry). Marriott’s second-quarter 2017 earnings beat expectations and increased year over year. Notably, with the purchase of Starwood, Marriott became the world's largest hotel company. In fact, the acquisition is likely to result in a bigger brand with increased scale and a robust development pipeline in the long run.
The Zacks analyst likes Marriott’s rising North-American business, sizeable international exposure and attractive brand-position. Further, its investments in technology for hotel bookings will improve guest experience, which in turn should boost occupancy. Yet lingering political uncertainties in key international markets, oversupply in some regions and currency headwinds might continue to limit revenue growth. Integration risks linked to Starwood purchase is an added concern.
(You can read the full research report on Marriott here >>>).
Enbridge’s shares have declined -1.9% over the last one year, significantly underperforming the Zacks Oil & Gas Production industry’s gain of +5.7% during the aforesaid period. The company has the longest and most sophisticated crude and liquids pipeline system in the world that spreads over 17,511 miles.
The Zacks analyst likes the merger with Spectra Energy as it has made Enbridge the largest energy infrastructure company in North America in terms of enterprise value. Also, the transaction has given Enbridge the industry’s largest backlog of growth projects, worth around C$75 billion. The company believes that this huge backlog will help it to grow its dividend by 10–12% annually from 2018 to 2024.
However, the company’s substantial debt load is a matter of concern. Also, during second-quarter 2017, Enbridge reported lower-than-expected results owing to higher operating expenses and accelerated maintenance work at the upstream operations of customers.
(You can read the full research report on Enbridge here >>>).
Other noteworthy reports we are featuring today include MetLife (MET), Deutsche Bank (DB) and Aon (AON).
3 Stocks to Ride a 588% Revenue Explosion
At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...
By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. See Zacks' Top 3 Stocks to Ride This Space >>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Get the latest research report on MAR - FREE
Get the latest research report on DB - FREE
Get the latest research report on MET - FREE
Get the latest research report on CVS - FREE
Get the latest research report on AON - FREE
Get the latest research report on ENB - FREE